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Objective. To examine the changes in health-related quality of life (HRQoL) in patients with coronary artery disease (CAD) in
terms of age, gender, and treatment strategy in Iran. Methods and Materials. Forty-nine patients responded to the Iranian version
of the 36-item short form (SF-36) questionnaire to evaluate the HRQoL at ﬁrst and third year after treatment. The paired and
independentWilcoxonrank-sumtestswereusedforwithinandbetweencomparisons,respectively.Multivariateregressionanalysis
was used to analyze the predictors of changes at HRQoL. Results. In general, during followup, the mental component summary
scale improved, and the physical component summary scale declined. The results of multiple regression showed that the score
at the ﬁrst year post-treatment was the main predictor of HRQoL at follow up. Moreover, after adjusting for other covariates,
receiving PTCA and being at older age were related to lower scores at followup, but these were not statistically signiﬁcant in most
cases. Conclusion. The HRQoL signiﬁcantly changed from one to three years after treatment in patients with CAD. While, the
physical health deteriorated during two-year follow up, mental health improved at the same time period. Generally, there were no
signiﬁcant diﬀerences at changes of HRQoL in terms of treatment, age, and gender.
1.Background
Health-related quality of life (HRQoL) shows a subjective
and multidimensional concept that is composed of a range
of domains, generally including physical, social, emotional,
mental, and functional health [1].
It is believed that the traditional end points, which are
mainly focused on the biologic and physiologic outcomes,
may not capture the impact of the intervention on patients’
HRQoL. As a result, a growing interest has appeared during
the past decades for assessing and measuring the impact
of diseases and their treatments on the patients’ QoL,
especially in long-term and chronic diseases [2]. Coronary
artery disease (CAD) is one of these chronic diseases which
impair the patient’s functional capacity and quality of life
[3, 4].
CAD is the ﬁrst cause of death in Iran and accounts for
46% of all cause of deaths in the country [5]. The prevalence
of the major risk factors for CAD is increasing in Iran [6]
and it warns for more burden of disease in the future. In
spiteofthisfact,littlehasbeenknownaboutthepredictorsof
HRQoL in patients with CAD in Iran. This provides a useful
decision tool for policymakers when planning for provision
of health services for these patients.
Previous studies have shown that treatment; gender, and
age are some potential predictors of HRQoL in these patients2 Cardiology Research and Practice
Table 1: Patients’ characteristics at the ﬁrst round interview (ﬁrst
year post-treatment).
Variable CABG PTCA
No. of patients 24 25
Median time since intervention (months) 10.94 8.84
Male (%) 66.66 80.00
Age (mean ± SD) 51.75
(8.46)
49.28
(6.53)
Age-groups (years old)
<50 (frequency) 12 11
50–60 (frequency) 9 12
60 and older 3 2
Covered by health insurance plan (%) 100.00 100.00
[7–9]. The aim of current study was to evaluate the changes
in HRQoL in patients with CAD, in terms of treatment type,
age and gender, during the two-year followup, between one-
to three-year post-treatment periods.
2. Method and Material
In a prospective cohort design, among patients with CAD
whounderwentPTCAorCABGbetweenMarch1st2007and
September 31st 2008 in two hospitals in Tehran, 49 consecu-
tive patients who met inclusion criteria were included in the
study. Inclusion criteria were (a) living in city of Tehran, (b)
having two or three vessel coronary artery diseases, (c) no
preposingdisease,and(d)consenttoparticipateinthestudy.
A culturally comparable questionnaire of the Short Form
Health Survey (SF-36) [10] has been developed, translated,
and validated previously in the Iranian population [11]. The
current study utilized this Iranian version of the SF-36 in
order to evaluate the HRQoL of the patients with CAD. The
questionnaire includes multi-item scales to assess the eight
dimensionsofwellness:physicalfunctioning,rolelimitations
due to physical health problems, bodily pain, general health
perceptions, social functioning, vitality, energy or fatigue,
and role limitations due to emotional problems. In addition,
two summary scores are calculated using these eight scales:
physicalcomponentsummary(PCS)andmentalcomponent
summary (MCS).
Each of the subscales is scored on a scale of 0–100, with
higher scores indicating better HRQoL. The summary com-
ponents were calculated using the mean value of each score
for the Iranian population [11] and the coeﬃcients from a
US study [12].
This questionnaire has been extensively used to examine
the HRQoL in cardiac patients [8, 13, 14]. Moreover, a recent
study in Iran has shown that SF-36 is a valid and reliable tool
for assessing the HRQoL in patients with CAD [15].
The ﬁrst round post-treatment interviews were done
between January and May 2009. Patients were followed to
April and May 2011 when they were interviewed for the
second time. Both interview rounds were conducted by face
to face contact.
2.1. Statistical Analysis. Two types of statistical analyses were
applied, univariate and multivariate analysis. In univariate
analysis, due to skewness in HRQoL data, the paired
Wilcoxon rank-sum test was used to detect any signiﬁcant
changes in HRQoL during the followup. Moreover, indepen-
dent Wilcoxon rank-sum test was used to test if there is any
signiﬁcant diﬀerence in HRQoL in terms of treatment, age,
and gender. Finally, multiple regression analysis was used to
examine the main predictors of changes in HRQoL during
the study period. Data were analyzed using STATA statistical
package, version 11 [16].
3. Results
Altogether, 49 patients participated in the current study,
24 of whom underwent the CABG and 25 received PTCA.
Table 1 shows the characteristics of the patients at the time
of ﬁrst interview in both treatment groups. Mean age was
51.75 (±8.46) and 49.28 (6.53) in CABG and PTCA groups,
respectively. On average, patients in both groups received the
treatment about one year prior to the ﬁrst round interview
(P = 0.219).
The median of followup was 25.6 months. Table 2 shows
the SF-36 subscales scores in the total sample in the ﬁrst
round and follow-up interviews. There was positive corre-
lation between physical and mental components summary
scalesintwointerviews(r1 = 0.171;P = 0.24andr2 = 0.299;
P = 0.04). In general, physical functioning, role-emotional,
mental health, and mental components summary scales
improved signiﬁcantly during the followup. On the other
hand, bodily pain, social functioning, and physical compo-
nents summary scales deteriorated in the same period. The
greatest improvement (41.69%) and decline (12.10%) were
seen in mental health and social functioning, respectively.
Table 3 showstheresultsofunivariateanalysisintermsof
treatment. Patients experienced signiﬁcant improvements in
mental health and mental component summary scales dur-
ing the followup. However, the level of physical component
summarydecreasedatthesameperiod.Therewerenosignif-
icant diﬀerences in changes of HRQoL during the followup
between two treatment groups (Table 3,l a s tc o l u m n ) .
The results of univariate analysis for gender groups
have been shown in Table 4. Males and females experienced
signiﬁcant improvements in 3 out of 10 scales during the fol-
lowup. On the other hand, four and one scales signiﬁcantly
deteriorated during the followup in both males and females,
respectively. Except for role-physical scale, the directions of
changes in men were similar to women. Only the change
in the physical functioning score was signiﬁcantly diﬀerent
between males and females (Table 4,l a s tc o l u m n ) .
Table 5 presents the HRQoL experiences in terms of age
groups. The median age at the baseline was used as a cut-
oﬀ point. Mental health and mental component summary
scores increased between the two interview periods in both
age groups, while the social functioning declined. The higher
number of scales deteriorated for older patients compared
withy oungerones(4v ersus1).Ex c eptforr ole-ph ysicalscale,
the directions of changes in scales were similar in the twoCardiology Research and Practice 3
Table 2: Comparison of the HRQoL scores at the ﬁrst and third year post-treatment.
First year (SD) Third year (SD) Change (%) P-value
Physical functioning 79.47 (26.96) 84.32 (23.91) 6.10 0.036
Role-physical 80.61 (30.34) 75.51 (32.07) −6.33 0.302
Bodily pain 80.29 (24.88) 73.06 (26.62) −9.00 0.016
General health 63.39 (20.45) 58.07 (23.97) −8.39 0.063
Vitality 61.52 (22.81) 66.78 (18.13) 8.55 0.229
Social functioning 80.94 (27.32) 71.15 (25.52) −12.10 <0.001
Role-emotional 75.53 (41.82) 87.24 (30.12) 15.50 0.007
Mental health 54.81 (25.93) 77.66 (16.94) 41.69 <0.001
Physical component summary 50.35 (9.86) 46.07 (10.51) −8.50 0.001
Mental component summary 48.01 (12.93) 54.99 (8.58) 14.54 <0.001
Table 3: The HRQoL scores at the ﬁrst and third year post-treatment in CABG and PTCA treatment groups.
CABG (n = 24) PTCA (n = 25) Between groups
comparison
Baseline (SD) Followup
(SD) P-value Baseline (SD) Followup
(SD) P-value P-value
Physical functioning 79.41 (21.80) 84.21 (19.01) 0.174 79.53 (31.59) 84.42 (28.24) 0.078 0.716
Role-physical 80.21 (31.26) 73.96 (31.69) 0.450 81.00 (30.00) 77.00 (33.09) 0.529 0.692
Bodily Pain 76.95 (22.66) 73.39 (25.31) 0.333 83.50 (26.90) 72.75 (28.35) 0.027 0.120
General health 65.89 (18.34) 64.02 (21.02) 0.797 61.00 (22.41) 52.36 (25.62) 0.042 0.101
Vitality 61.61 (23.15) 70.60 (15.32) 0.056 61.43 (22.96) 63.11 (20.09) 0.925 0.134
Social functioning 87.50 (22.42) 73.95 (20.68) 0.003 74.64 (30.43) 68.46 (29.62) 0.082 0.285
Role-emotional 86.13 (33.92) 93.04 (19.68) 0.307 65.36 (46.63) 81.68 (37.11) 0.008 0.158
Mental health 54.46 (23.91) 81.58 (9.94) <0.001 55.14 (28.24) 73.89 (21.19) 0.002 0.215
Physical component summary 49.72 (9.30) 45.98 (9.90) 0.032 50.96 (10.52) 46.16 (11.27) 0.015 0.631
Mental component summary 49.89 (11.59) 57.49 (4.25) 0.002 46.20 (14.10) 52.59 (10.85) 0.020 0.535
groups. Older patients experienced higher changes in role-
physical scale than younger ones (Table 5,l a s tc o l u m n ) .
The results of multivariate analysis have been presented
in Table 6. Patients with the higher score at the ﬁrst year
post-treatment had a higher score at the follow-up. After
control for other covariates, older patients, on average, had
lower scores at role-physical and role-emotional scales than
younger ones in the followup. There were no signiﬁcant
diﬀerences in HRQoL between CABG and PTCA groups,
after control for other covariates. The follow-up score of
social functioning was higher for males than females. Vari-
ations explained by the regression models ranged between
22% in role-physical scale and 48% in vitality scale.
4. Discussion
The changes of HRQoL are considered as an important out-
come in treatment guidelines in diﬀerent medical ﬁelds. In
the current study the changes of HRQoL in the patients with
CAD during the period of one to three years after treatment
wereexaminedtoseeiftypeoftreatment;ageandgendercan
explain the diﬀerences in HRQoL in these patients.
During the followup, based on mental and physical com-
ponent summary scales, the mental health signiﬁcantly
improved while the physical health deteriorated. These
changes in mental and physical health were in line with pre-
vious studies [17, 18].
It should be noted that physical functioning was
improved signiﬁcantly during the followup, but physi-
cal health as measured by physical component summary
declined. In all age, gender, and treatment groups, the great-
est improvements were seen in the mental health scale. Gen-
erally, the size and direction of changes in HRQoL between
age, gender, and treatment groups were similar.
In terms of treatment groups (CABG versus PTCA),
although both groups experienced signiﬁcant changes in
HRQoL during the followup, there were no signiﬁcant
diﬀerences in these changes between the two groups. The
signiﬁcant changes in HRQoL after treatment in both
t r e a t m e n tg r o u p sw e r er e p o r t e di np r e v i o u ss t u d i e s[ 3, 8].
In addition, previous studies have shown that the diﬀerences
in HRQoL between CABG and PTCA become smaller over
time, and the diﬀerences are not signiﬁcant during the
followup [19–21].
The number of the SF-36 scales which signiﬁcantly
changed during the followup was higher for males than4 Cardiology Research and Practice
Table 4: The HRQoL scores at the ﬁrst and third year post-treatment in based on gender.
Male (n = 36) Female (n = 13) Between groups
comparison
Baseline (SD) Followup
(SD) P-value Baseline (SD) Followup
(SD) P-value P-value
Physical functioning 85.95 (21.48) 87.43 (22.20) 0.482 61.54 (32.98) 75.71 (27.22) 0.008 0.016
Role-physical 88.89 (20.22) 78.47 (26.83) 0.096 57.69 (41.31) 67.31 (43.76) 0.571 0.207
Bodily pain 85.12 (22.24) 76.08 (22.99) 0.003 66.92 (27.72) 64.71 (34.51) 0.859 0.112
General health 67.19 (20.18) 61.36 (20.08) 0.020 52.88 (17.97) 48.95 (31.61) 0.753 0.303
Vitality 64.88 (21.35) 69.29 (14.64) 0.315 52.20 (24.98) 59.83 (24.86) 0.553 0.910
Social functioning 83.76 (26.63) 75.80 (21.47) 0.013 73.12 (28.75) 58.27 (31.87) 0.019 0.355
Role-emotional 76.86 (42.03) 88.19 (27.51) 0.033 71.85 (42.69) 84.62 (37.55) 0.084 0.698
Mental health 58.13 (26.90) 79.24 (12.95) <0.001 45.60 (21.34) 73.28 (25.10) 0.002 0.292
Physical component summary 53.09 (7.61) 47.56 (9.21) <0.001 42.77 (11.63) 41.97 (13.02) 0.807 0.160
Mental component summary 48.61 (13.71) 55.79 (7.51) 0.001 46.34 (10.77) 52.78 (11.09) 0.028 0.651
Table 5: The HRQoL scores at the ﬁrst and third year post-treatment based on the age groups.
<50 years old (n = 23) ≥50 years old (n = 26) Between groups
comparison
Baseline (SD) Followup
(SD) P-value Baseline (SD) Followup
(SD) P-value P-value
Physical functioning 91.30 (14.06) 94.05 (11.37) 0.105 69.00 (31.28) 75.71 (28.64) 0.138 0.663
Role-physical 83.70 (25.68) 88.04 (24.85) 0.420 77.88 (34.15) 64.42 (34.04) 0.022 0.045
Bodily pain 85.11 (22.27) 82.55 (15.30) 0224 76.03 (26.68) 64.66 (31.60) 0.027 0.618
General health 66.85 (22.96) 61.26 (17.81) 0.153 60.34 (17.85) 55.24 (28.39) 0.286 0.405
Vitality 68.94 (19.09) 72.22 (13.40) 0.891 54.95 (24.14) 61.97 (20.53) 0.127 0.237
Social functioning 89.17 (20.34) 79.91 (13.24) 0.008 73.65 (30.84) 63.40 (31.04) 0.023 0.746
Role-emotional 79.74 (38.57) 96.74 (13.99) 0.055 71.81 (44.91) 78.85 (37.59) 0.046 0.467
Mental health 65.84 (21.75) 84.21 (9.52) 0.001 45.05 (25.78) 71.86 (19.91) <0.001 0.109
Physical component summary 52.63 (5.81) 49.63 (6.59) 0.114 48.33 (12.16) 42.93 (12.33) 0.003 0.155
Mental component summary 51.72 (10.28) 57.59 (3.74) 0.029 44.72 (14.29) 52.70 (10.84) 0.001 0.271
Table 6: Results of multiple regression analyses∗.
SF-36 subscales
Physical
functioning
Role-
physical
Bodily
pain
General
health Vitality Social
functioning
Role-
emotional
Mental
health
Physical
component
summary
Mental
component
summary
Score at ﬁrst-year ∗∗ 0.488a 0.268 0.506a 0.340c 0.382a 0.488a 0.433a 0.184c 0.557a 0.298a
≥50 years old −8.281 −22.916b −13.620c −2.815 −4.388 −9.927 −14.748b −8.947c −4.483c −2.842
PTCA −0.961 3.257 −3.558 −11.313 −8.154c −2.176 −1.711 −8.718c −0.552 −4.222c
Male 2.289 2.645 2.110 10.229 6.366 15.132b 1.102 5.513 0.322 3.047
Interval 1∗∗ 0.039 0.016 0.001 0.006 0.005 0.044c −0.000 0.017 0.008 0.004
Interval 2∗∗ −0.093 −0.013 0.039 −0.043 −0.019 −0.090 0.032 0.003 −0.016 0.007
Constant 87.521a 88.898 80.553a 57.821a 68.591a 66.407a 95.134a 82.803a 48.498a 56.416a
R-squared 0.462 0.220 0.333 0.225 0.479 0.462 0.463 0.311 0.373 0.397
∗The scores at followup were regressed on covariates.
a, b and c denote the signiﬁcance level at the 1, 5, and 10%, respectively.
∗∗These covariates transformed as mean centering.Cardiology Research and Practice 5
females (7 versus 4). Generally, male had higher scores at
the followup than females, after control for other covariates;
but it was only statistically signiﬁcant for social functioning.
Previous studies have shown that, generally, the level of
HRQoL for males is higher than females in patients with
CAD [7, 22].
Both younger and older patients experienced signiﬁcant
changes in HRQoL from one- to three-year post-treatment
period. After adjusting for other covariates, older patients
had lower scores in role-physical and role-emotional scales
at the followup than younger patients. In a previous study,
H¨ ofer et al. [23] found that older patients with CAD had a
lowerlevelofabilitytoperformphysicaltasks.WorseHRQoL
for older patients with CAD was also reported by Unsar et al.
[22].
The scores at the ﬁrst interview round were the main
predictorsofthefollow-upscores.Patientswithahigherlevel
of HRQoL at one-year post-treatment experienced a higher
level of HRQoL over three years after the treatment. Hence,
the eﬀects of treatments on HRQoL during ﬁrst year after
treatment can be used as a measure for long-term eﬀects of
treatment in patients with CAD.
The ﬁndings of current study expand the body of
knowledge about HRQoL among the patients who suﬀer
from the leading cause of deaths in Iran. However, the results
of this study should be interpreted in light of a number of
limitations. The number of patients in the study was small
and it may aﬀect the produced results. Although, nonran-
domization design raises the chance of biases in our study,
it reﬂects the routine practice in the country. Moreover,
SF-36 is a general instrument to measure the HRQoL and
may have not captured the aspects of HRQoL which is
speciﬁc to CAD. Using the disease-speciﬁc instruments and
comparing the results with general instruments is an agenda
for future research. Furthermore, the cultural adjustment in
SF-36 for using in the Iranian population may constrain the
direct comparison of the current study with studies in other
countries and hence limit the generalizability of its results to
other jurisdictions.
5. Conclusion
The HRQoL signiﬁcantly changed from one to three years
after the treatment in the patients with CAD. While the
physical health deteriorated during the two-year followup,
mental health improved at the same time. Generally, there
were no signiﬁcant diﬀerences in HRQoL changes in terms
of treatment strategy, age, and gender. HRQoL at the ﬁrst
yearaftertreatmentisanimportantpredictorofHRQoLover
long-term followup.
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